Wockhardt Limited (NSE:WOCKPHARMA)
1,356.70
-8.60 (-0.63%)
Nov 6, 2025, 2:30 PM IST
Wockhardt Revenue
Wockhardt had revenue of 8.03B INR in the quarter ending September 30, 2025, a decrease of -0.74%. This brings the company's revenue in the last twelve months to 30.09B, up 0.94% year-over-year. In the fiscal year ending March 31, 2025, Wockhardt had annual revenue of 30.35B with 7.24% growth.
Revenue (ttm)
30.09B
Revenue Growth
+0.94%
P/S Ratio
7.37
Revenue / Employee
13.11M
Employees
2,296
Market Cap
221.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 30.35B | 2.05B | 7.24% |
| Mar 31, 2024 | 28.30B | 1.73B | 6.51% |
| Mar 31, 2023 | 26.57B | -5.73B | -17.74% |
| Mar 31, 2022 | 32.30B | 5.22B | 19.28% |
| Mar 31, 2021 | 27.08B | -1.36B | -4.78% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 550.12B |
| Aurobindo Pharma | 320.25B |
| Cipla | 279.66B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Wockhardt News
- 5 weeks ago - Wockhardt submits NDA to US FDA for novel antibacterial Zidebactam-Cefepime - Business Upturn
- 5 weeks ago - Wockhardt shares fall over 5% after Trump’s pharma tariff announcement - Business Upturn
- 2 months ago - Shukra Pharmaceuticals secures Pan-India distribution rights from Wockhardt - Business Upturn
- 3 months ago - Wockhardt Q1 Results: Shares drop 3% as EBITDA falls 20.9% YoY Rs 72 crore, revenue flat at Rs 739 - Business Upturn
- 4 months ago - Wockhardt shares jump 4% after exiting loss-making US generics business - Business Upturn
- 4 months ago - Wockhardt exits US generics business to focus on innovative portfolio - Business Upturn
- 6 months ago - Senores Pharmaceuticals acquires USFDA-approved ANDA for Enalapril Maleate Tablets from Wockhardt - Business Upturn
- 6 months ago - Senores Pharmaceuticals share price jumps 3% after company acquires ANDA for Topiramate tablets from Wockhardt - Business Upturn